NCT06540066 2026-03-16
A Study of BGB-B3227 Alone and in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Terminated
BeOne Medicines
BeOne Medicines
BeOne Medicines
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Jiangsu Cancer Institute & Hospital
Gustave Roussy, Cancer Campus, Grand Paris